Related Experiment Video

Updated: Jul 12, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Does myectomy convey survival benefit in hypertrophic cardiomyopathy?

Anna Woo1, Harry Rakowski

  • 1University of Toronto, Toronto, ON, Canada. anna.woo@uhn.on.ca <anna.woo@uhn.on.ca>

Heart Failure Clinics
|August 29, 2007
PubMed

Insights

Transaortic subaortic myectomy effectively treats obstructive hypertrophic cardiomyopathy (HCM), improving symptoms and outflow tract obstruction. This review evaluates myectomy

Area of Science:

  • Cardiology
  • Cardiovascular Surgery

Background:

  • Obstructive hypertrophic cardiomyopathy (HCM) is a significant cardiovascular condition.
  • Transaortic subaortic myectomy is a primary surgical intervention for obstructive HCM.
  • Alternative treatments like dual chamber pacing and septal ethanol ablation exist.

Purpose of the Study:

  • To review the clinical course and outcomes of obstructive HCM.
  • To evaluate the risks, benefits, and survival impact of myectomy.
  • To compare surgical myectomy with conservative and alternative therapies.

Main Methods:

  • Literature review of clinical studies on obstructive HCM.
  • Analysis of early and long-term surgical outcomes.
  • Comparison of surgical versus non-surgical management strategies.

Main Results:

  • Myectomy improves symptoms and abolishes left ventricular outflow tract obstruction in obstructive HCM patients.
  • Surgical outcomes and survival rates are key considerations.
  • Comparative data on myectomy versus other interventions are examined.

Conclusions:

  • Transaortic subaortic myectomy is a proven treatment for obstructive HCM.
  • Careful evaluation of risks, benefits, and survival is crucial when choosing HCM therapy.
  • Myectomy remains a benchmark for comparison against emerging treatments.

More Related Videos

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...